|View printer-friendly version|
|Stereotaxis Secures First Niobe(R) System Order in Japan|
The new customer's Niobe system will be part of a reconstructed, state-of-the-art hospital facility. Construction is expected to be complete in early 2015 and reflects the hospital's commitment to advance its medical care through the latest equipment, therapies and integrated services.
"We are proud to offer the first comprehensive robotic solution for the delivery of cardiac ablation therapy in such an important market as
Dr. Nakagawa, an internationally recognized EP physician and researcher, has assisted in educating physicians and the Japanese government on the clinical benefits of the Niobe system through live case demonstrations, presentations at major industry events and personal discussions.
Leading these and other efforts to build out
The core components of
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the
CONTACT: Investor Contact: